

# Wolfgang Bergmeier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2975219/publications.pdf>

Version: 2024-02-01

98  
papers

4,650  
citations

126907

33  
h-index

98798

67  
g-index

112  
all docs

112  
docs citations

112  
times ranked

5029  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic deletion of platelet PAR4 results in reduced thrombosis and impaired hemostatic plug stability. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 422-433.	3.8	9
2	Fibrin(ogen) engagement of <i>S. aureus</i> promotes the host antimicrobial response and suppression of microbe dissemination following peritoneal infection. <i>PLoS Pathogens</i> , 2022, 18, e1010227.	4.7	10
3	Deletion of platelet CLEC-2 decreases GPIIb/IIIa-mediated integrin $\alpha$ IIb $\beta$ 3 activation and decreases thrombosis in TTP. <i>Blood</i> , 2022, , .	1.4	13
4	Rasa3 deficiency minimally affects thrombopoiesis but promotes severe thrombocytopenia due to integrin-dependent platelet clearance. <i>JCI Insight</i> , 2022, 7, .	5.0	6
5	Hypofibrinogenemia with preserved hemostasis and protection from thrombosis in mice with an <i>Fga</i> truncation mutation. <i>Blood</i> , 2022, 139, 1374-1388.	1.4	12
6	Fast clearance of platelets in a commonly used mouse model for GPIIb/IIIa is impeded by an anti-GPIIb/IIIa antibody derivative. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1451-1463.	3.8	3
7	Both G protein-coupled and immunoreceptor tyrosine-based activation motif receptors mediate venous thrombosis in mice. <i>Blood</i> , 2022, 139, 3194-3203.	1.4	13
8	Specifications of the variant curation guidelines for <i>ITGA2B</i> / <i>ITGB3</i> : ClinGen Platelet Disorder Variant Curation Panel. <i>Blood Advances</i> , 2021, 5, 414-431.	5.2	19
9	Heightened activation of embryonic megakaryocytes causes aneurysms in the developing brain of mice lacking podoplanin. <i>Blood</i> , 2021, 137, 2756-2769.	1.4	11
10	The Small Gtpase Rap1 in Platelets Is Critical for Arterial but Not Venous Thrombosis in Mice. <i>Blood</i> , 2021, 138, 2131-2131.	1.4	0
11	Subcellular localization of Rap1 GTPase activator CalDAG-GEFI is orchestrated by interaction of its atypical C1 domain with membrane phosphoinositides. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 693-705.	3.8	6
12	Platelet transfusion for patients with platelet dysfunction: effectiveness, mechanisms, and unanswered questions. <i>Current Opinion in Hematology</i> , 2020, 27, 378-385.	2.5	6
13	Megakaryocytes use in vivo podosome-like structures working collectively to penetrate the endothelial barrier of bone marrow sinusoids. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2987-3001.	3.8	28
14	Development of Optimized Tissue-Factor-Targeted Peptide Amphiphile Nanofibers to Slow Noncompressible Torso Hemorrhage. <i>ACS Nano</i> , 2020, 14, 6649-6662.	14.6	28
15	Talin-1 is the principal platelet Rap1 effector of integrin activation. <i>Blood</i> , 2020, 136, 1180-1190.	1.4	52
16	Novel Mouse Model for Studying Hemostatic Function of Human Platelets. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 1891-1904.	2.4	7
17	Therapeutic strategies for thrombosis: new targets and approaches. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 333-352.	46.4	188
18	Platelets trigger perivascular mast cell degranulation to cause inflammatory responses and tissue injury. <i>Science Advances</i> , 2020, 6, eaay6314.	10.3	32

#	ARTICLE	IF	CITATIONS
19	Desialylation of <i>O</i>-glycans on glycoprotein Ib $\alpha$ drives receptor signaling and platelet clearance. <i>Haematologica</i> , 2020, 106, 220-229.	3.5	22
20	Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 538-564.	3.4	64
21	Glanzmann thrombasthenia: genetic basis and clinical correlates. <i>Haematologica</i> , 2020, 105, 888-894.	3.5	75
22	Impact of Platelet Count on Bleeding in the Setting of Anti-Platelet Therapy. <i>Blood</i> , 2020, 136, 18-18.	1.4	0
23	RAP GTPases and platelet integrin signaling. <i>Platelets</i> , 2019, 30, 41-47.	2.3	34
24	Small GTPases in megakaryocyte and platelet biology. <i>Platelets</i> , 2019, 30, 7-8.	2.3	2
25	New insights into cytoskeletal remodeling during platelet production. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1430-1439.	3.8	26
26	Platelet Signal Transduction. , 2019, , 329-348.		5
27	Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease. <i>Blood</i> , 2019, 133, 2529-2541.	1.4	51
28	Ether lipid metabolism by AADACL1 regulates platelet function and thrombosis. <i>Blood Advances</i> , 2019, 3, 3818-3828.	5.2	7
29	Impaired hemostatic activity of healthy transfused platelets in inherited and acquired platelet disorders: Mechanisms and implications. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	14
30	Calcium-induced structural rearrangements release autoinhibition in the Rap-GEF CalDAG-GEFI. <i>Journal of Biological Chemistry</i> , 2018, 293, 8521-8529.	3.4	16
31	Anticoagulant Protein S Targets the Factor IXa Heparin-Binding Exosite to Prevent Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 816-828.	2.4	23
32	Platelets at the vascular interface. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 27-33.	2.3	17
33	Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 407-428.	2.3	5
34	Platelet Signaling Pathways and New Inhibitors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, e28-e35.	2.4	41
35	Marked bleeding diathesis in patients with platelet dysfunction due to a novel mutation in <i>RASGRP2</i>, encoding CalDAG-GEFI (p.Gly305Asp). <i>Platelets</i> , 2018, 29, 84-86.	2.3	20
36	Identification of two novel mutations in <i>RASGRP2</i> affecting platelet CalDAG-GEFI expression and function in patients with bleeding diathesis. <i>Platelets</i> , 2018, 29, 192-195.	2.3	26

#	ARTICLE	IF	CITATIONS
37	Two novel, putative mechanisms of action for citalopram-induced platelet inhibition. <i>Scientific Reports</i> , 2018, 8, 16677.	3.3	13
38	RAS P21 Protein Activator 3 (RASA3) Specifically Promotes Pathogenic T Helper 17 Cell Generation by Repressing T-Helper-2-Cell-Biased Programs. <i>Immunity</i> , 2018, 49, 886-898.e5.	14.3	15
39	STIM1 R304W causes muscle degeneration and impaired platelet activation in mice. <i>Cell Calcium</i> , 2018, 76, 87-100.	2.4	21
40	Rap1 binding to the talin 1 FO domain makes a minimal contribution to murine platelet GPIIb-IIIa activation. <i>Blood Advances</i> , 2018, 2, 2358-2368.	5.2	30
41	Functional redundancy between RAP1 isoforms in murine platelet production and function. <i>Blood</i> , 2018, 132, 1951-1962.	1.4	43
42	Effects of ibrutinib treatment on murine platelet function during inflammation and in primary hemostasis. <i>Haematologica</i> , 2017, 102, e89-e92.	3.5	20
43	The Phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) Binder Rasa3 Regulates Phosphoinositide 3-kinase (PI3K)-dependent Integrin $\alpha$ IIb $\beta$ 3 Outside-in Signaling. <i>Journal of Biological Chemistry</i> , 2017, 292, 1691-1704.	3.4	36
44	Phenotype analysis and clinical management in a large family with a novel truncating mutation in RASGRP2, the CalDAG-GEFI encoding gene. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 128-133.	2.3	14
45	Deletion of the Arp2/3 complex in megakaryocytes leads to microthrombocytopenia in mice. <i>Blood Advances</i> , 2017, 1, 1398-1408.	5.2	33
46	CalDAG-GEFI Deficiency Reduces Atherosclerotic Lesion Development in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 792-799.	2.4	20
47	Acquired platelet disorders. <i>Thrombosis Research</i> , 2016, 141, S73-S75.	1.7	20
48	Synthesis and dephosphorylation of MARCKS in the late stages of megakaryocyte maturation drive proplatelet formation. <i>Blood</i> , 2016, 127, 1468-1480.	1.4	34
49	Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction. <i>Blood</i> , 2016, 128, 1282-1289.	1.4	68
50	Mice Expressing Low Levels of CalDAG-GEFI Exhibit Markedly Impaired Platelet Activation With Minor Impact on Hemostasis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1838-1846.	2.4	18
51	Integrins Form an Expanding Diffusional Barrier that Coordinates Phagocytosis. <i>Cell</i> , 2016, 164, 128-140.	28.9	163
52	RAP1-GTPase signaling and platelet function. <i>Journal of Molecular Medicine</i> , 2016, 94, 13-19.	3.9	69
53	Phenotype Analysis and Clinical Management in a Large Family with a Novel Truncating Mutation in RASGRP2, the Caldag-GEFI Encoding Gene. <i>Blood</i> , 2016, 128, 3713-3713.	1.4	1
54	Rap1 and its effector RIAM are required for lymphocyte trafficking. <i>Blood</i> , 2015, 126, 2695-2703.	1.4	78

#	ARTICLE	IF	CITATIONS
55	RASA3 is a critical inhibitor of RAP1-dependent platelet activation. <i>Journal of Clinical Investigation</i> , 2015, 125, 1419-1432.	8.2	113
56	Platelet Inhibitors Reduce Rupture in a Mouse Model of Established Abdominal Aortic Aneurysm. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2032-2041.	2.4	61
57	Platelet signaling - blood's great balancing act. <i>Oncotarget</i> , 2015, 6, 19922-19923.	1.8	2
58	Ibrutinib-Treated Platelets Secure Vascular Integrity in Inflammation. <i>Blood</i> , 2015, 126, 2235-2235.	1.4	0
59	Platelet Immunoreceptor Tyrosine-Based Activation Motif (ITAM) Signaling and Vascular Integrity. <i>Circulation Research</i> , 2014, 114, 1174-1184.	4.5	58
60	Adoptive transfer method to study platelet function in mouse models of disease. <i>Thrombosis Research</i> , 2014, 133, S3-S5.	1.7	13
61	A talin mutant that impairs talin-integrin binding in platelets decelerates $\alpha$ IIb $\beta$ 3 activation without pathological bleeding. <i>Blood</i> , 2014, 123, 2722-2731.	1.4	40
62	Chemoproteomic Discovery of AADACL1 as a Regulator of Human Platelet Activation. <i>Chemistry and Biology</i> , 2013, 20, 1125-1134.	6.0	19
63	Emerging roles of store-operated $Ca^{2+}$ entry through STIM and ORAI proteins in immunity, hemostasis and cancer. <i>Channels</i> , 2013, 7, 379-391.	2.8	105
64	Platelet ITAM signaling is critical for vascular integrity in inflammation. <i>Journal of Clinical Investigation</i> , 2013, 123, 908-16.	8.2	194
65	The Parallel Signaling Pathways Of Phosphatidylserine (PS) Exposure Downstream Of Platelet $Fc\gamma$ RIIa. <i>Blood</i> , 2013, 122, 3514-3514.	1.4	2
66	Desensitization of the P2Y 1 receptor in platelets. <i>FASEB Journal</i> , 2013, 27, 1172.3.	0.5	0
67	Gamma Prime Fibrinogen Does Not Cause Arterial Thrombosis. <i>Blood</i> , 2013, 122, 1092-1092.	1.4	1
68	Abstract 130: Platelet Rap1 Signaling, Mediated by CalDAG-GEFI and P2Y12, Contributes to Atherosclerotic Lesion Development in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, .	2.4	0
69	Extracellular Matrix Proteins in Hemostasis and Thrombosis. <i>Cold Spring Harbor Perspectives in Biology</i> , 2012, 4, a005132-a005132.	5.5	124
70	Rap1-Rac1 Circuits Potentiate Platelet Activation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 434-441.	2.4	60
71	Abstract 53: Immunoreceptor Tyrosine Activation Motif Signaling in Platelets Is Critical for the Maintenance of Vascular Integrity During Inflammation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, .	2.4	0
72	Identification of AADACL1 As a Novel Regulator of Human Platelets Via Chemoproteomics. <i>Blood</i> , 2012, 120, 381-381.	1.4	0

#	ARTICLE	IF	CITATIONS
73	The kinetics of $\alpha\text{IIb}\beta_3$ activation determines the size and stability of thrombi in mice: implications for antiplatelet therapy. <i>Blood</i> , 2011, 117, 1005-1013.	1.4	71
74	Formation of Procoagulant Platelets in Heparin-Induced Thrombocytopenia (HIT) Follows a Unique Signaling Pathway. <i>Blood</i> , 2011, 118, 197-197.	1.4	0
75	Inhibition of Sialic Acid Loss Greatly Improves Survival of Refrigerated Platelets. <i>Blood</i> , 2011, 118, 1133-1133.	1.4	0
76	STIM1 Deficiency Results In Impaired Platelet Procoagulant Activity and Protection From Arterial Thrombosis. <i>Blood</i> , 2010, 116, 485-485.	1.4	13
77	Critical Role of CalDAG-GEFI In $\text{FCI}^3\text{RIIa}$ -Dependent Platelet Activation and Thrombosis. <i>Blood</i> , 2010, 116, 3196-3196.	1.4	0
78	CalDAG-GEFI is at the nexus of calcium-dependent platelet activation. <i>Blood</i> , 2009, 114, 2506-2514.	1.4	134
79	Revised Model for Platelet Adhesion to Collagen.. <i>Blood</i> , 2009, 114, 2999-2999.	1.4	0
80	Transfection of Human Platelets Down-Regulates Endogenous mRNA.. <i>Blood</i> , 2009, 114, 4026-4026.	1.4	0
81	The Signaling Molecule CalDAG-GEFI Represents a Novel Target for Antithrombotic Therapy.. <i>Blood</i> , 2009, 114, 1077-1077.	1.4	0
82	Glycoprotein $\text{Ib}\beta_3$ and von Willebrand factor in primary platelet adhesion and thrombus formation: Lessons from mutant mice. <i>Thrombosis and Haemostasis</i> , 2008, 99, 264-270.	3.4	75
83	CalDAG-GEFI and protein kinase C represent alternative pathways leading to activation of integrin $\alpha\text{IIb}\beta_3$ in platelets. <i>Blood</i> , 2008, 112, 1696-1703.	1.4	129
84	Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type III. <i>Journal of Clinical Investigation</i> , 2007, 117, 1699-1707.	8.2	170
85	Metalloproteinase Inhibitors Increase the Survival of Long-Term Refrigerated Platelets in Mice.. <i>Blood</i> , 2007, 110, 419-419.	1.4	3
86	CalDAG-GEFI and Protein Kinase C (PKC) Represent Alternative Pathways Leading to Activation of Integrin $\alpha\text{IIb}\beta_3$ in Platelets.. <i>Blood</i> , 2007, 110, 3646-3646.	1.4	0
87	The role of platelet adhesion receptor GPIb far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 16900-16905.	7.1	213
88	The Role of Platelet Adhesion Receptor GPIb Far Exceeds That of Its Main Ligand von Willebrand Factor in Arterial Thrombosis.. <i>Blood</i> , 2006, 108, 1797-1797.	1.4	21
89	Mice Lacking the Signaling Molecule, CalDAG-GEFI, Represent a Mouse Model for Leukocyte Adhesion Deficiency Type III.. <i>Blood</i> , 2006, 108, 674-674.	1.4	0
90	Differential Changes in Platelet VWF Receptor Following Refrigeration for Short or Long Periods.. <i>Blood</i> , 2005, 106, 3564-3564.	1.4	0

#	ARTICLE	IF	CITATIONS
91	GPVI down-regulation in murine platelets through metalloproteinase-dependent shedding. <i>Thrombosis and Haemostasis</i> , 2004, 91, 951-958.	3.4	79
92	Tumor Necrosis Factor- $\alpha$ -Converting Enzyme (ADAM17) Mediates GPIIb/IIIa Shedding From Platelets In Vitro and In Vivo. <i>Circulation Research</i> , 2004, 95, 677-683.	4.5	224
93	CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. <i>Nature Medicine</i> , 2004, 10, 982-986.	30.7	348
94	GPIIb/IIIa Is Essential for Platelet Adhesion during Thrombus Formation: Studies with Mutant Mice Deficient in the Extracellular Domain of GPIIb/IIIa. <i>Blood</i> , 2004, 104, 3659-3659.	1.4	0
95	Flow cytometric detection of activated mouse integrin $\alpha$ IIb $\beta$ 3 with a novel monoclonal antibody. <i>Cytometry</i> , 2002, 48, 80-86.	1.8	136
96	Long-Term Antithrombotic Protection by in Vivo Depletion of Platelet Glycoprotein VI in Mice. <i>Journal of Experimental Medicine</i> , 2001, 193, 459-470.	8.5	321
97	Rhodocytin (Aggretin) Activates Platelets Lacking $\alpha$ 2 $\beta$ 1 Integrin, Glycoprotein VI, and the Ligand-binding Domain of Glycoprotein IIb/IIIa. <i>Journal of Biological Chemistry</i> , 2001, 276, 25121-25126.	3.4	76
98	Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. <i>Blood</i> , 2000, 96, 2520-2527.	1.4	258